Opendata, web and dolomites

mP-CSE

Micro-physiological circadian platform for safety and efficacy assessment of drugs and cosmetics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 mP-CSE project word cloud

Explore the words cloud of the mP-CSE project. It provides you a very rough idea of what is the project "mP-CSE" about.

scaled    organs    platforms    dynamics    cosmetic       turn    microphysiological    smart    animals    adjusting    rhythms    chip    withdrawal    costly    treatment    global    laboratory    medications    medicines    effect    13    biotechnology    employees    organ    drugs    function    predicting    enhances    69    groundbreaking    2025    commercialization    drug    tested    rhythm    human    models    seeking    3d    huge    cagr    roi    risky    vascular    latest    single    platform    billion    time    toxic    alternative    sensing    safe    5b    body    technologies    efficacy    heart    humans    physiological    dose    reduce    maximum    multiple    circadian    pharmaceutical    mimic    helping    tissue    hire    brain    precise    functionally    detect    food    chips    liver    moc    limitations    patients    proven    compounds    companies    innovation    animal    rate    kidney    ltd    uses    schemes       stress    tests    incorporation    administration    70    ultimately    company    market   

Project "mP-CSE" data sheet

The following table provides information about the project.

Coordinator
TISSUE DYNAMICS LTD 

Organization address
address: PARK HI-TECH, GIVAT RAM
city: JERUSALEM
postcode: 91904
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.tissuedynamics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TISSUE DYNAMICS LTD IL (JERUSALEM) coordinator 50˙000.00

Map

 Project objective

Tissue Dynamics Ltd. is a groundbreaking biotechnology company focused on developing smart microphysiological platform technologies for drug, food, and cosmetic development. Pharmaceutical and cosmetic companies face huge costs of developing and testing new products (an average of €2.5B to develop a single drug), which is increasing over the years. Traditionally, these tests have been carried out in animal models whose limitations in predicting human responses are significant (70% of drugs toxic to humans are not toxic to animals). These limitations lead to the withdrawal of many drugs in the market, making drug development a costly risky process. Organ-on-chip platforms, developed in recent years, have proven to be a better alternative to current laboratory models, offering more physiological and similar characteristics to the human body. Tissue Dynamics goal is to provide a functionally scaled Multi Organ-on-Chip (MOC) platform that uses real-time sensing of tissue function to detect the effect of drug-induced physiological stress in multiple 3D vascular organs (liver, heart, brain, kidney). Our latest innovation has been the incorporation of factors that mimic circadian rhythms in the organs, which is essential to test the physiological impact of the compounds tested. On the other hand, the incorporation of the circadian rhythm in our chips enhances the development of treatment schemes, adjusting in a more precise way the dose and the time of administration of the medications, seeking the maximum efficacy of them. The global Organ-on-Chip market is a rapidly-growing, estimated to reach $6.13 Billion by 2025, with an expected growth rate of CAGR 69.4%. Our platform will reduce the cost of new drugs development ultimately, helping patients by making more safe and effective medicines reach the market. In turn we expect ROI of 5 after five years of commercialization and hire 10 new employees.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MP-CSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MP-CSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

LOLAS (2019)

Precise and reliable autonomous landing for drones, helicopters and other rotorcraft

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More